LNX1 contributes to cell cycle progression and cisplatin resistanceopen access
- Authors
- Jang, M.; Park, R.; Park, Y.-I.; Park, Y.; Lee, J.I.; Namkoong, S.; Lee, E.-J.; Park, J.
- Issue Date
- Aug-2021
- Publisher
- MDPI AG
- Keywords
- Cell cycle; Cell death; Cisplatin; LNX1
- Citation
- Cancers, v.13, no.16
- Journal Title
- Cancers
- Volume
- 13
- Number
- 16
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/49476
- DOI
- 10.3390/cancers13164066
- ISSN
- 2072-6694
2072-6694
- Abstract
- The ligand of numb-protein X1 (LNX1) acts as a proto-oncogene by inhibiting p53 stability; however, the regulation of LNX1 expression has not been investigated. In this study, we screened chemicals to identify factors that potentially regulate LNX1 expression. We found that LNX1 expression levels were decreased by DNA damage, including that by cisplatin. Upon treatment with lipopolysaccharide (LPS) and phorbol 12-myristate 13-acetate (PMA), LNX1 expression levels in-creased. In addition, cell-cycle progression increased upon LNX1 expression; the levels of S and G2/M populations were correlated with LNX1 expression. Moreover, in CRISPR-Cas9-mediated LNX1 knockout cells, we observed a delay in cell-cycle progression and a downregulation of genes encoding the cell-cycle markers cyclin D1 and cyclin E1. Finally, the upregulation of LNX1-activated cell-cycle progression and increased resistance to cisplatin-mediated cell death. Taken together, these results suggest that LNX1 contributes to cell-cycle progression and cisplatin resistance. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.